CSIMarket
 
Illumina Inc   (NASDAQ: ILMN)
 

Illumina Inc's Customers Performance

ILMN



 
ILMN's Source of Revenues During the corresponding time, Illumina Inc recorded a revenue increase by 9.44 % year on year, sequentially revenue grew by 6.23 %. While revenue at the Illumina Inc 's corporate clients

List of ILMN Customers




for the same period Illumina Inc recorded revenue increase by 9.44 % year on year, sequentially revenue grew by 6.23 %.

List of ILMN Customers

Illumina Inc's Business Units
Product    163.85 % of total Revenue
Service    30.37 % of total Revenue
Sequencing    176.79 % of total Revenue
Microarray    17.43 % of total Revenue
Consumables    142.28 % of total Revenue
Instruments    21.57 % of total Revenue
United States and Canada    107.25 % of total Revenue
EMEA    62.55 % of total Revenue
China    9.32 % of total Revenue
Asia Pacific    15.1 % of total Revenue
Core Illumina    194.22 % of total Revenue






Illumina Inc's Comment on Sales, Marketing and Customers



The company serves customers across multiple markets, including genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical companies, biotechnology companies, commercial molecular diagnostic laboratories, and consumer genomics companies. Its products support research and clinical applications by offering integrated sequencing and microarray systems, consumables, and analysis tools designed to accommodate various genomic complexities, price points, and throughput requirements. On June 24, 2024, the company completed the spin-off of GRAIL into a new public company, distributing shares to its stockholders while retaining a minority stake.





Illumina Inc’s Comment on Sales, Marketing and Customers


The company serves customers across multiple markets, including genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical companies, biotechnology companies, commercial molecular diagnostic laboratories, and consumer genomics companies. Its products support research and clinical applications by offering integrated sequencing and microarray systems, consumables, and analysis tools designed to accommodate various genomic complexities, price points, and throughput requirements. On June 24, 2024, the company completed the spin-off of GRAIL into a new public company, distributing shares to its stockholders while retaining a minority stake.








ILMN's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Illumina Inc 33,387.66 4,393.00 853.00 1,280
SUBTOTAL 0.00 0.00 0.00 -

Sources: Illumina Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Illumina Inc’s corporate clients.
For your research, we’ve provided 9 tables on Illumina Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.